Second International Urology Cancer Summit

27.09.24 – Portsmouth, UK

Time zone is BST (British Summer Time)

09:00

Welcome by Chairs

Giuseppe Luigi Banna (UK) & Ravindran Kanesvaran (Singapore)

Urothelial Cancer

09:05 – 09:25

The role of immunotherapy in the evolving treatment landscape of UC

Simon Crabb, Southampton, UK

09:25- 09:45

Shall we treat mUTUC in a different way

Patrizia Giannatempo, Milan, Italy

09:45 – 10:05

Contemporary options in non-metastatic bladder cancer 

Param Mariappan, Edinburgh, UK

10:05 – 10:25

Who is suitable for bladder sparing treatment in 2024?

Ananya Choudhury, Manchester, UK

Diagnostics and Biomarkers

10:25 – 10:45

Staging by imaging: Where we stand in prostate cancer

Akash Maniam, Portsmouth, UK

10:45 – 11:05

Liquid vs tumour biopsy in urological tumours

Christian Rolfo, New York, US

11:05 – 11:20

Coffee Break – (ePoster Session)

Prostate Cancer

11:20 – 11:40

Treatment escalation and de-escalation in mHSPC

Pasquale Rescigno, Newcastle, UK

11:40 – 12:00

How first- and second-line treatment of mCRPC is evolving

Neeraj Agarwal, Salt Lake City, US

12:00 – 12:20

Patient-friendly fractionation for localised disease

Alison Tree, London, UK

12:20 – 13:25

Industry Symposia

13:20 – 14:15

Lunch – (ePoster Session)

14:15 – 15:20

Industry Symposia

Renal

15:20 – 15:40

Intensification and de-intensification in the treatment of mRCC

Monty Pal, Los Angeles, US

15:40 – 16:00

Updating treatment sequencing for mRCC

Naveen Vasudev, Leeds, UK

16:00 – 16:20

Clinical case quiz

Yüksel Ürün, Ankara, Turkey

16:20 – 16:35

Coffee break (ePoster Session – award)

Real-world

16:35 – 16:55

Inequity as a barrier to access

Ravindran Kanesvaran, Singapore

16:55 – 17:15

The relevance of QoL outcomes in clinical trials and the real world

Laura Marandino, London, UK

17:15

Closure remarks